Phase 2 drug trial offers hope to patients with advanced colorectal cancer
29. 08. 2012 | ecancer.org
A new drug treatment could offer hope to patients with advanced colorectal cancer who were intolerant of or did not respond to standard treatments, according to an article published in The Lancet Oncology [1].
Image credit: shutterstock.com
The drug – called TAS-102 – was tested on 169 patients in Japan with inoperable, metastatic (spreading) colorectal cancer.
The patients had already undergone several rounds of standard chemotherapy, to no effect, or were intolerant of standard drug treatments (which include irinotecan, oxaliplatin, and a group of drugs known as fluoropyrimidines).
Read the whole article at ecancer.org
Reference
- Yoshino T, Mizunuma N, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. The Lancet Oncology 2012. doi: 10.1016/S1470-2045(12)70345-5
Keywords: metastatic colorectal cancer, survival time
